Back to News
Market Impact: 0.3
India's Cipla misses second-quarter profit view on muted US sales
Source: reuters.com
Corporate EarningsHealthcare & BiotechCompany FundamentalsAnalyst Estimates
Cipla, India's third-largest drugmaker by revenue, missed second-quarter profit estimates. Muted sales of generic Revlimid and stiff competition weighed on its US business; the article gives no profit or sales figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
More News
- SK Hynix Posts Record Profit Amid AI Rush
- SK Hynix third-quarter profit sharply beats estimates on AI memory boost
- Anthropic's IPO could be 'speculative fiction' or a 'generational moment' — investors are split
- Tech's relief rally extends as attention turns to tough decisions for the Fed
- Anthropic Gives Traders a Pure-Play Bet on Frontier AI
- Analysis-Hold or sell? High Treasury yields spur US banks to rethink bond portfolios